Avanos Medical, Inc. $AVNS Shares Bought by Punch & Associates Investment Management Inc.

Punch & Associates Investment Management Inc. grew its holdings in shares of Avanos Medical, Inc. (NYSE:AVNS) by 61.9% in the first quarter, Holdings Channel reports. The institutional investor owned 437,085 shares of the company’s stock after purchasing an additional 167,085 shares during the period. Punch & Associates Investment Management Inc.’s holdings in Avanos Medical were worth $6,124,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. JPMorgan Chase & Co. raised its position in shares of Avanos Medical by 116.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 577,889 shares of the company’s stock worth $6,680,000 after acquiring an additional 311,317 shares in the last quarter. Tudor Investment Corp ET AL lifted its stake in Avanos Medical by 509.6% during the third quarter. Tudor Investment Corp ET AL now owns 71,893 shares of the company’s stock worth $831,000 after purchasing an additional 60,099 shares during the last quarter. Thrivent Financial for Lutherans boosted its holdings in Avanos Medical by 38.0% in the fourth quarter. Thrivent Financial for Lutherans now owns 212,215 shares of the company’s stock valued at $2,383,000 after purchasing an additional 58,451 shares in the last quarter. UBS Group AG boosted its holdings in Avanos Medical by 7.9% in the fourth quarter. UBS Group AG now owns 415,107 shares of the company’s stock valued at $4,662,000 after purchasing an additional 30,290 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its stake in Avanos Medical by 1,596,514.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 14,896,413 shares of the company’s stock valued at $167,287,000 after purchasing an additional 14,895,480 shares during the last quarter. 95.17% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on AVNS shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Avanos Medical in a report on Monday, July 20th. Wall Street Zen cut shares of Avanos Medical from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Finally, Zacks Research raised shares of Avanos Medical from a “strong sell” rating to a “hold” rating in a research report on Friday, June 5th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Reduce”.

Avanos Medical Stock Up 0.1%

Avanos Medical stock opened at $25.00 on Friday. Avanos Medical, Inc. has a fifty-two week low of $9.30 and a fifty-two week high of $25.49. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.40 and a current ratio of 2.48. The company has a market capitalization of $1.17 billion, a P/E ratio of -15.52 and a beta of 1.57. The stock has a 50-day simple moving average of $24.91 and a 200-day simple moving average of $19.25.

Avanos Medical (NYSE:AVNS) last announced its earnings results on Tuesday, May 5th. The company reported $0.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.16 by $0.06. The firm had revenue of $182.20 million during the quarter, compared to analysts’ expectations of $170.00 million. Avanos Medical had a positive return on equity of 5.39% and a negative net margin of 10.39%.The business’s revenue was up 8.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.26 EPS. Equities research analysts expect that Avanos Medical, Inc. will post 1.06 earnings per share for the current year.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.